A phase II trial to evaluate the combination of ZD1839 (Iressa) and fulvestrant (Faslodex) in patients with advanced or metastatic breast cancer.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Fulvestrant (Primary) ; Gefitinib
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 18 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 13 Nov 2005 New trial record.